

OSCTR Biostatistics, Epidemiology and Research Design Core

WORKSHOP

PHASE 1 CLINICAL TRIAL DESIGNS

Daniel Zhao, Ph.D.

Professor

Department of Biostatistics and Epidemiology

Hudson College of Public Health

University of Oklahoma

Wednesday, September 16th, 2026

12:00 PM – 1:00 PM

Virtual: Zoom

Meeting ID: 995 6940 4592

Passcode: 04220740

DATE: September 16th, 2026

TIME: 12:00 PM – 1:00 PM

FORMAT: By Zoom

PREREQUISITES:

- Basic statistical knowledge is sufficient for this talk.

DESCRIPTION:

Phase 1 clinical trials play a critical role in early drug development by evaluating safety and identifying appropriate doses for further clinical investigation. This presentation will introduce the statistical principles and practical considerations underlying Phase 1 studies. Topics will include dose-limiting toxicities, selection and spacing of dose levels, dose–toxicity relationships, and determination of the maximum tolerated dose (MTD).

The session will review and compare several commonly used Phase 1 trial designs, including the traditional 3+3 design, the model-based Continual Reassessment Method (CRM), and the model-assisted Bayesian Optimal Interval (BOIN) design.

END OF WORKSHOP EVALUATION SURVEY:

- You will also receive the link by email after the workshop:
- https://qualtrics.ou.edu/jfe/form/SV_8p7xiDApsrudCPs

SPONSOR ACKNOWLEDGEMENT:

- Sponsored by the Clinical Epidemiology Unit of the Biostatistics and Epidemiology Research Design (BERD) Core of the Oklahoma Shared Clinical and Translational Resources (OSCTR)
- National Institutes of Health, National Institute of General Medical Sciences Grant U54GM104938

Speaker BIOGRAPHICAL SUMMARY:

Dr. Daniel Zhao is Professor of Biostatistics at OUHSC. He is a member of the Biostatistics, Epidemiology, and Research Design Core of the Oklahoma Shared Clinical and Translational Resources (OSCTR). He is also the Associate Director of the Biostatistics Research Design and Shared Resources at the Stephenson Cancer Center. Previously, he worked at University of Texas Southwestern Medical Center and Eli Lilly. He obtained a Bachelor in Mathematics from Peking University and a PhD in Statistics from the Iowa State University. His research areas included longitudinal data analysis, misclassification, and adaptive clinical trial designs.